Death, Sudden, Cardiac
Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
Subtype terms (1)
More specific conditions that are subtypes of Death, Sudden, Cardiac in the MeSH hierarchy.
Drugs by status
Phase 4 trials (4)
Phase 3 trials (17)
Phase 2 trials (5)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (44)
- GlaxoSmithKline
- Pronova BioPharma
- National Heart, Lung, and Blood Institute (NHLBI)
- Atlantic Health System
- Baylor University
- Boston University
- Harvard University
- Dartmouth University
- Duke University
- Emory University
- Geisinger Clinic
- University of Washington
- Henry Ford Health System
- Maimonides Medical Center
- Northwell Health
- Northwestern University
- Rhode Island Hospital
- Rutgers University
- Stiftung Institut fuer Herzinfarktforschung
- University of Nebraska
- University of Rochester
- University of South Carolina
- University of Southern California
- Aspirus Heart and Vascular Institute-Research and Education
- State University of New York
- University of California, Berkeley
- University of California, Davis
- University of California, San Francisco
- University of Utah
- Icahn School of Medicine at Mount Sinai
- +14 more
Organization Involved with Phase 2 Indications (6)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (6)